{"filing":{"accession_number":"0001104659-26-065231","cik":"0001761612","ticker":"BCYC","company_name":"BICYCLE THERAPEUTICS PLC","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tm2615187d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926065231/tm2615187d1_8k.htm"},"events":[{"id":9345,"run_id":8198,"accession_number":"0001104659-26-065231","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, impairment, litigation, etc.), warranting classification as other_material.","company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":951,"accession_number":"0001104659-26-065231","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, impairment, litigation, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:33:51.664137+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":951,"accession_number":"0001104659-26-065231","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, impairment, litigation, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:33:51.664137+00:00","company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","filing_date":"2026-05-21"}]}